Immunotherapy drug nivolumab ruled too costly for head and neck cancer patients – Belfast Telegraph
Belfast Telegraph |
Immunotherapy drug nivolumab ruled too costly for head and neck cancer patients
Belfast Telegraph … doctors will not be able to offer this game-changing immunotherapy to patients with advanced head and neck cancer. "Once it has relapsed or spread, the disease is extremely difficult to treat and options, including surgery and radiotherapy, are … Nivolumab not recommend for relapsed or metastatic head-and-neck cancer on the NHS |
